
    
      All participants must be enrolled on protocol, "Collection of Specimens and Clinical Data
      from Patients with Renal Cell Carcinoma Treatment with Targeted Therapies", about to start a
      treatment course with sunitinib and AMG386, and willing to come in for successive MRIs at the
      following times: baseline, 2 weeks upon initiation of therapy with sunitinib and AMG386,
      after cycle 2 and/or cycle 4 of therapy, and at the end of your study therapy.
    
  